FI3840837T3 - Arginaasin estäjät ja menetelmät niiden käyttämiseksi - Google Patents
Arginaasin estäjät ja menetelmät niiden käyttämiseksi Download PDFInfo
- Publication number
- FI3840837T3 FI3840837T3 FIEP19758683.7T FI19758683T FI3840837T3 FI 3840837 T3 FI3840837 T3 FI 3840837T3 FI 19758683 T FI19758683 T FI 19758683T FI 3840837 T3 FI3840837 T3 FI 3840837T3
- Authority
- FI
- Finland
- Prior art keywords
- aza
- oxa
- oxo
- hydroxy
- amino
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- HMZBZPGFUGYYIH-UHIISALHSA-N (2S)-2-amino-N-[(3R,5R)-10-hydroxy-12-oxo-11-oxa-1-aza-10-boraspiro[4.7]dodecan-3-yl]-3-methylbutanamide Chemical compound N[C@H](C(=O)N[C@H]1CN[C@]2(C1)C(OB(CCCC2)O)=O)C(C)C HMZBZPGFUGYYIH-UHIISALHSA-N 0.000 claims 1
- -1 2-amino-N-((3R,5R)-8-hydroxy-6-oxo-7-oxa-1-aza-8-boraspiro[4.7]dodecan-3-yl)-3-methylbutanamide Chemical compound 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721113P | 2018-08-22 | 2018-08-22 | |
| PCT/EP2019/072341 WO2020038983A1 (en) | 2018-08-22 | 2019-08-21 | Arginase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3840837T3 true FI3840837T3 (fi) | 2024-06-03 |
Family
ID=67742403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19758683.7T FI3840837T3 (fi) | 2018-08-22 | 2019-08-21 | Arginaasin estäjät ja menetelmät niiden käyttämiseksi |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11952392B2 (enExample) |
| EP (2) | EP4371614A3 (enExample) |
| JP (1) | JP7441210B2 (enExample) |
| KR (1) | KR102668252B1 (enExample) |
| CN (1) | CN112584900B (enExample) |
| AU (1) | AU2019323663B2 (enExample) |
| CA (1) | CA3109100A1 (enExample) |
| CL (1) | CL2021000430A1 (enExample) |
| DK (1) | DK3840837T3 (enExample) |
| EA (1) | EA202190532A1 (enExample) |
| ES (1) | ES2980252T3 (enExample) |
| FI (1) | FI3840837T3 (enExample) |
| HR (1) | HRP20240694T1 (enExample) |
| HU (1) | HUE066903T2 (enExample) |
| IL (1) | IL280924B2 (enExample) |
| LT (1) | LT3840837T (enExample) |
| MA (1) | MA53427B1 (enExample) |
| MX (1) | MX2021002042A (enExample) |
| PL (1) | PL3840837T3 (enExample) |
| PT (1) | PT3840837T (enExample) |
| RS (1) | RS65608B1 (enExample) |
| SG (1) | SG11202101618PA (enExample) |
| SI (1) | SI3840837T1 (enExample) |
| SM (1) | SMT202400221T1 (enExample) |
| WO (1) | WO2020038983A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (zh) | 2018-07-05 | 2023-12-29 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| MY206577A (en) * | 2019-02-08 | 2024-12-24 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| EP4239652A4 (en) | 2020-12-25 | 2024-06-05 | Sumitomo Riko Company Limited | Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| AU2016281620B2 (en) * | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| US11291674B2 (en) * | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US12215116B2 (en) | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| WO2019205979A1 (zh) | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
-
2019
- 2019-08-21 MA MA53427A patent/MA53427B1/fr unknown
- 2019-08-21 PL PL19758683.7T patent/PL3840837T3/pl unknown
- 2019-08-21 SI SI201930758T patent/SI3840837T1/sl unknown
- 2019-08-21 RS RS20240642A patent/RS65608B1/sr unknown
- 2019-08-21 CA CA3109100A patent/CA3109100A1/en active Pending
- 2019-08-21 EA EA202190532A patent/EA202190532A1/ru unknown
- 2019-08-21 KR KR1020217007915A patent/KR102668252B1/ko active Active
- 2019-08-21 EP EP24162089.7A patent/EP4371614A3/en active Pending
- 2019-08-21 FI FIEP19758683.7T patent/FI3840837T3/fi active
- 2019-08-21 CN CN201980055111.3A patent/CN112584900B/zh active Active
- 2019-08-21 ES ES19758683T patent/ES2980252T3/es active Active
- 2019-08-21 HR HRP20240694TT patent/HRP20240694T1/hr unknown
- 2019-08-21 IL IL280924A patent/IL280924B2/en unknown
- 2019-08-21 WO PCT/EP2019/072341 patent/WO2020038983A1/en not_active Ceased
- 2019-08-21 EP EP19758683.7A patent/EP3840837B1/en active Active
- 2019-08-21 PT PT197586837T patent/PT3840837T/pt unknown
- 2019-08-21 JP JP2021509794A patent/JP7441210B2/ja active Active
- 2019-08-21 DK DK19758683.7T patent/DK3840837T3/da active
- 2019-08-21 AU AU2019323663A patent/AU2019323663B2/en active Active
- 2019-08-21 SM SM20240221T patent/SMT202400221T1/it unknown
- 2019-08-21 LT LTEPPCT/EP2019/072341T patent/LT3840837T/lt unknown
- 2019-08-21 US US17/269,569 patent/US11952392B2/en active Active
- 2019-08-21 HU HUE19758683A patent/HUE066903T2/hu unknown
- 2019-08-21 MX MX2021002042A patent/MX2021002042A/es unknown
- 2019-08-21 SG SG11202101618PA patent/SG11202101618PA/en unknown
-
2021
- 2021-02-19 CL CL2021000430A patent/CL2021000430A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202193007A1 (ru) | Соединения пирролидина | |
| HRP20240694T1 (hr) | Inhibitori arginaze i postupci njihove upotrebe | |
| FI4084791T3 (fi) | Spesifisiä tryptamiinejä käytettäviksi mielialahäiriöiden hoidossa | |
| GEP20237568B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| BR112021026682A2 (pt) | Compostos e métodos para inibir eif4e | |
| JP2016532667A5 (enExample) | ||
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| PH12021552930A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EA202090987A8 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
| WO2015187542A8 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| TN2022000255A1 (en) | Pyrrolopyrimidine amines as complement inhibitors | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| RU2019105794A (ru) | Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат | |
| EP4233871A3 (en) | Inhibiting the transient receptor potential a1 ion channel | |
| ZA202102241B (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2021014944A (es) | Metodos para tratar cancer usando inhibidores de prmt5. | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| RU2012105044A (ru) | Цитратная соль 9е-15-(2-пирролидин-1-ил-этокси)-7,12,25-триокса-19,21,24-триазатетрацикло[18.3.1.1(2,5).1(14,18)]гексакоза-1( 24 ),2,4,9,14,16,18( 26 ),20,22-нонаена | |
| RU2021137929A (ru) | Ингибитор egfr для лечения рака | |
| MX2025010543A (es) | Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion | |
| RU2021111402A (ru) | Морфические формы ингибиторов фактора d комплемента |